Table of Contents

Section I

Office of Drug Evaluation V
Division of Analgesic, AntiInflammatory and Ophthalmic Drugs

Tab 1: Office Director's Memorandum, Jonca C. Bull, M.D.
Tab 2: Division Director's Memorandum, Lee S. Simon, M.D.
Tab 3: Arava Review: Lee S. Simon, M.D.
Tab 4: Arava Review: Lawrence Goldkind, M.D.
Appendix A: Study Report, Risks in DMARDs in RA
Appendix B: Medwatch Reports

Section II

Office of Drug Safety

Tab 1: Memorandum, Paul J. Seligman, M.D., M.P.H.
Tab 2: Memorandum, Victor F. C. Raczkowski, M.D., M.S.
Tab 3: Memorandum, David J. Graham, M.D., M.P.H.
Renan A. Bonnel, Pharm. D., M.P.H.
Tab 4: Memorandum, Lauren Lee, Pharm.D.

Section III

Consultants

Tab 1: Rheumatology Expert: Steven B. Abramson, M.D.
Tab 2: Hepatology Experts: A. Leonard B. Seeff, M.D.
B. James H. Lewis, M.D.
Tab 3: Epidemiology/Statistics Expert: Robert W. Makuch, Ph.D.

Section IV

Reference Documents

Tab 1: Citizens Petition: Health Research Group
Tab 2: Aventis Response to Citizens Petition
Tab 3: Public Response to Citizens Petition: Gary S. Firestein, M.D.
Tab 4: Health Assessment Questionnaire (HAQ)